Review of dalbavancin, a novel semisynthetic lipoglycopeptide

Expert Opinion on Investigational Drugs

Volumn 16, Issue 5, 2007, Pages 717-733

  Kim, Aryun ^a   Kuti, Joseph L ^a   Nicolau, David P ^a,b  

^a Center for Anti Infective Research and Development   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

BI 397; Dalbavancin; Lipoglycopeptide

Indexed keywords

A 40926; A A 1; AZTREONAM; CEFALEXIN; CEFAZOLIN; CEFTAZIDIME; CEFTRIAXONE; CLINDAMYCIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GAMMA GLUTAMYLTRANSFERASE; GENTAMICIN; GLYCOPEPTIDE; LACTATE DEHYDROGENASE; LEVOFLOXACIN; LINEZOLID; LIPOGLYCOPEPTIDE; MDL 63397; METRONIDAZOLE; ORITAVANCIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; PROCAINE PENICILLIN; RIFAMPICIN; TEICOPLANIN; TEICOPLANIN DERIVATIVE; TELAVANCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VER 001; ZEVEN;

ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BLOOD DISEASE; CATHETER INFECTION; CATHETER REMOVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DIALYSIS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR DISEASE; FACE EDEMA; FATIGUE; GASTROINTESTINAL TOXICITY; GRAM POSITIVE BACTERIUM; GRANULOMA; HEART DISEASE; HUMAN; HYPERGLYCEMIA; INSOMNIA; KIDNEY DISEASE; KIDNEY FAILURE; LEUKOPENIA; LOADING DRUG DOSE; LOBAR PNEUMONIA; LOOSE FECES; MAINTENANCE DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; MULTIPLE DRUG DOSE; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; OTOTOXICITY; PANCYTOPENIA; PHARMACODYNAMICS; PRURITUS; QT INTERVAL; SEPTICEMIA; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VESTIBULAR DISORDER; VOMITING;

ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LIPOPROTEINS; MICROBIAL SENSITIVITY TESTS; TEICOPLANIN; TREATMENT OUTCOME;

EID: 34248207301     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.5.717     Document Type: Article

References (66)

1. NATIONAL NOSOCOMIAL INFECTIONS SURVEILLANCE (NNIS): system report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control. (2004) 32(8):470-485.
2. MORAN GJ, KRISHNADASAN A, GORWITZ RJ et al.: Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. (2006) 355(7):666-674.
3. SALGADO CD, FARR BM, CALFEE DF: Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin. Infect. Dis. (2003) 36(2):131-139.
4. NAIMI TS, LEDELL KH, COMO-SABETTI K et al.: Comparison of community and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA (2003) 290(22):2976-2984.
5. CENTERS FOR DISEASE CONTROL AND PREVENTION: Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb. Mortal. Wkly Rep. (2002) 51(26):565-567.
6. CENTERS FOR DISEASE CONTROL AND PREVENTION: Public health dispatch: vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. MMWR Morb. Mortal. Wkly Rep. (2002) 51(40):902.
7. CENTERS FOR DISEASE CONTROL AND PREVENTION: Brief report: vancomycin-resistant Staphylococcus aureus-New York, 2004. MMWR Morb. Mortal. Wkly Rep. (2004) 53(15):322-323.
8. ZHU W, WEIGEL LM, CLARK NC, MCDOUGAL LK, PATEL JB: Characterization of three Michigan vancomycin-resistant Staphylococcus aureus and vanA plasmids from associated vancomycin-resistant Enterococcus. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (27 - 30 September 2006):C2-608.
9. COSGROVE SE, CARMELI Y: The impact of antimicrobial resistance on health and economic outcomes. Clin. Infect. Dis. (2003) 36(11):1433-1437.
10. COSGROVE SE, SAKOULAS G, PERENCEVICH EN, SCHWABER MJ, KARCHMER AW, CARMELI Y: Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. (2003) 36(1):53-59.
11. SPELLBERG B, POWERS JH, BRASS EP, MILLER LG, EDWARDS JE Jr: Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. (2004) 38(9):1279-1286.
12. VAN BAMBEKE F: Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr. Opin. Pharmacol. (2004) 4(5):471-478.
13. MALABARBA A, GOLDSTEIN BP: Origin, structure, and activity in vitro and in vivo of dalbavancin. J. Antimicrob. Chemother. (2005) 55(S2):ii15-ii20.
14. VAN BAMBEKE F, LAETHEM YV, COURVALIN P, TULKENS PM: Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs (2004) 64(9):913-936.
15. MALABARBA A, CIABATTI R: Glycopeptide derivatives. Curr. Med. Chem. (2001) 8(14):1759-1773.
16. KAHNE D, LEIMKUHLER C, LU W, WALSH C: Glycopeptide and lipoglycopeptide antibiotics. Chem. Rev. (2005) 105(2):425-448.
17. BEAUREGARD DA, WILLIAMS DH, GWYNN MN, KNOWLES DJ: Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob. Agents Chemother. (1995) 39(3):781-785.
18. HIGGINS DL, CHANG R, DEBABOV DV et al.: Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (2005) 49(3):1127-1134.
19. JONES RN, BIEDENBACH DJ, JOHNSON DM, PFALLER MA: In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. J. Chemother. (2001) 13(3):244-254.
20. STREIT JM, FRITSCHE TR, SADER HS, JONES RN: Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn. Microbiol. Infect. Dis. (2004) 48(2):137-143.
21. PACE JL, YANG G: Glycopeptides: update on an old successful antibiotic class. Biochem. Pharmacol. (2006) 71(7):968-980.
22. JONES RN, STILWELL MG, SADER HS, FRITSCHE TR, GOLDSTEIN BP: Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn. Microbiol. Infect. Dis. (2006) 54(2):149-153.
23. JONES RN, FRITSCHE TR, SADER HS, GOLDSTEIN BP: Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J. Chemother. (2005) 17(6):593-600.
24. GALES AC, SADER HS, JONES RN: Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clin. Microbiol. Infect. (2005) 11(2):95-100.
25. LIN G, CREDITO K, EDNIE LM, APPELBAUM PC: Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob. Agents Chemother. (2005) 49(2):770-772.
26. LOPEZ S, HACKBARTH C, ROMANO G, TRIAS J, JABES D, GOLDSTEIN BP: In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J. Antimicrob. Chemother. (2005) 55(S2):ii21-ii24.
27. BIEDENBACH DJ, FRITSCHE TR, SADER HS, JONES RN: In vitro activity of dalbavancin susceptibility tested against Staphylococcus spp. and β-hemolytic Streptococcus spp. isolated in USA medical centers. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (27 - 30 September 2006):E-726.
28. FLAMM RK, DRAGHI DC, KARLOWSKY JA, SAHM DF: Activity of dalbavancin against clinical isolates of Staphylococci and Streptococci from the US and Europe. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (October 30 - November 2 2004):E-2008.
29. CUEVAS O, CERCENADO E, GOYANES MJ, MARIN M, CASTELLARES C, BOUZA E: Comparative in vitro activity of dalbavancin against recent clinical isolates of Staphylococcus spp. isolated in Spain. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (17-20 September 2006):C2-1141.
30. GOLDSTEIN EJ, CITRON DM, WARREN YA, TYRRELL KL, MERRIAM CV, FERNANDEZ HT: In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic Gram-positive isolates recovered from diabetic foot infections. Antimicrob. Agents Chemother. (2006) 50(8):2875-2879.
31. GOLDSTEIN BP, JONES RN, FRITSCHE TR, BIEDENBACH DJ: Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections. Diagn. Microbiol. Infect. Dis. (2006) 54(2):83-87.
32. CANDIANI G, ABBONDI M, BORGONOVI M, ROMANO G, PARENTI F: In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J. Antimicrob. Chemother. (1999) 44(2):179-192.
33. CARMELI Y, ROTHERMEL C, SHEEHAN D, HOGAN P, MENDELSON M: Analysis of patients with community-acquired methicillin-resistant Staphylococcus aureus in a Phase 3 study of dalbavancin versus linezolid for the treatment of complicated skin and soft tissue infections. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (27- 30 September 2006):L-1211.
34. STREIT JM, SADER HS, FRITSCHE TR, JONES RN: Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn. Microbiol. Infect. Dis. (2005) 53(4):307-310.
35. BOZDOGAN B, ESEL D, WHITENER C, BROWNE FA, APPELBAUM PC: Antibacterial susceptibility of vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. (2003) 52(5):864-868.
36. BOZDOGAN B, EDNIE L, CREDITO K, KOSOWSKA K, APPELBAUM PC: Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center. Antimicrob. Agents Chemother. (2004) 48(12):4762-4765.
37. BOWKER KE, NOEL AR, MACGOWAN AP: Antibacterial effect of dalbavancin against MSSA, MRSA and VISA in an in vitro pharmacokinetic system. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (October 30 - November 2 2004):A-1165.
38. LIN G, SMITH K, EDNIE LM, APPELBAUM PC: Antipneumococcal activity of dalbavancin compared to other agents. Antimicrob. Agents Chemother. (2005) 49(12):5182-5184.
39. GOLDSTEIN EJ, CITRON DM, MERRIAM CV, WARREN Y, TYRRELL K, FERNANDEZ HT: In vitro activities of dalbavancin and nine comparator agents against anaerobic Gram-positive species and corynebacteria. Antimicrob. Agents Chemother. (2003) 47(6):1968-1971.
40. HEINE HS, BASSETT J, MILLER L: In vitro and in vivo activity of dalbavancin against Bacillus anthracis. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (16 - 19 September 2005):F-2079.
41. FLAMM RK, DRAGHI DC, JONES ME, THORNS BERRY C, SAHM DF: Dalbavancin demonstrates a low potential for in vitro selection of resistance to staphylococci. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (16-19 December 2005):C1-1408.
42. JONES RN, SADER HS, FRITSCHE TR, HOGAN PA, SHEEHAN DJ: Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program. J. Clin. Microbiol. (2006) 44(7):2622-2625.
43. LEIGHTON A, GOTTLIEB AB, DORR MB et al.: Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob. Agents Chemother. (2004) 48(3):940-945.
44. CAVALERI M, COOPER A, NUTLEY MA, STOGNIEW M: Protein binding of dalbavancin using isothermal titration microcalorimetry. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (27 - 30 September 2002):A-1385.
45. CAVALERI M, RIVA S, VALAGUSSA A et al.: Pharmacokinetics and excretion of dalbavancin in the rat. J. Antimicrob. Chemother. (2005) 55(S2):ii31-ii35.
46. DOWELL JA, BUCKWALTER M, SELTZER E, STOGNIEW M: Dalbavancin penetration in to skin supports once weekly dosing. Clin. Microbiol. Infect. (2005) 11(52):272 (Abstract P-895).
47. BULGHERONI A, JABES D, POLLINI W et al.: Dalbavancin uptake by murine macrophages. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA (30 October - 2 November 2004):A-1490.
48. DOWELL J, SELTZER E, STOGNIEW M, DORR MB, FAYOCAVITZ S, KRAUSE D: Dalbavancin dosage adjustments not required for patients with mild renal impairment. Clin. Microbiol. Infect. (2003) 9(S1):291 (Abstract P-1224).
49. DOWELL JA, SELTZER E, KRAUSE D, HENKEL T: The safety and pharmacokinetics of dalbavancin in subjects with renal impairment or end-stage renal disease. Clin. Microbiol. Infect. (2005) 11(S2):272 (Abstact-P896).
50. DOWELL JA, SELTZER E, BUCKWALTER M, MARBURY T: The pharmacokinetics of dalbavancin in subjects with mild, moderate or severe hepatic impairment. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (30 October-2 November 2004):A-19.
51. BUCKWALTER M, DOWELL JA: Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J. Clin. Pharmacol. (2005) 45(11):1279-1287.
52. ANDES DR, CRAIG WA: In vivo pharmacodynamic characterization of dalbavancin in the routine thigh infection model. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (30 October - 2 November 2004):A-1872.
53. BOWKER KE, NOEL AR, MACGOWAN AP: Pharmacodynamics of dalbavancin in an in vitro pharmacokinetic system. J. Antimicrob. Chemother. (2006) 58(4):802-805.
54. JABES D, CANDIANI G, ROMANO G, BRUNATI C, RIVA S, CAVALERI M: Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob. Agents Chemother. (2004) 48(4):1118-1123.
55. CANDIANI GP, ROMANO G, CAVALERI M, RIVA S, JABES D: Efficacy of a single dalbavancin dose compared with multiple linezolid doses against penicillin-resistant pneumococci in a lobar pneumonia model in the immunocompetent rat. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA (22 - 25 December 2001):B-989.
56. LEFORT A, PAVIE J, GARRY L, CHAU F, FANTIN B: Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin. Antimicrob. Agents Chemother. (2004) 48(3):1061-1064.
57. DAROUICHE RO, MANSOURI MD: Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo. J. Infect. (2005) 50(3):206-209.
58. NORD CE, RASMANIS G, WAHLUND E: Effect of dalbavancin on the normal intestinal microflora. J. Antimicrob. Chemother. (2006) 58(3):627-631.
59. NORD C, SILLERSTROM E, WAHLUND E: New drugs for Gram-positive infections do not select for Clostridium difficile. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (17 - 20 September 2006):K-1016.
60. JOHNSON DM, FRITSCHE TR, SADER HS, JONES RN: Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. Int. J. Antimicrob. Agents (2006) 27(6):557-560.
61. SELZER E, DORR MB, GOLDSTEIN BP et al.: Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. (2003) 37(10):1298-1303.
62. JAUREGUI LE, BABAZADEH S, SELTZER E et al.: Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. (2005) 41(10):1407-1415.
63. GOLDSTEIN BP, SELTZER E, FLAMM R, SAHM D: Dalbavancin phase 3 skin and skin structure studies: pathogens and microbiological efficacy. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA (16- 19 December 2005):L-1577.
64. RAAD I, DAROUICHE R, VAZQUEZ J et al.: Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin. Infect. Dis. (2005) 40(3):374-380.
65. CAMPBELL KCM, KELLY E, TARGOVNIK N et al.: Audiologic monitoring for potential ototoxicity in a Phase 1 clinical trial of a new glycopeptide antibiotic. J. Am. Acad. Audiol. (2003) 14(3):157-168.
66. SELTZER E, GOLDBERG L, KRAUSE D: Safety of dalbavancin in a clinical development program. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (27 - 30 September 2006):L-1576.